FilingFirehose · free AI preview
Telomir Pharmaceuticals, Inc.
TELO · AI-generated SEC analysis preview · refreshes when data changes
⚠️ Red flag 8-Ks: 1
Types: Officer Departure
Telomir Pharmaceuticals (TELO) reported an officer departure on June 8, 2026, flagged in a Form 8-K filing—a material corporate event warranting closer examination. While a single departure doesn't indicate systemic distress, the timing and context matter significantly for investors evaluating management stability and execution risk. Our 90-day scan detected no cyber incidents, but officer transitions can signal underlying strategic shifts or governance concerns. The full $49 Report adds dilution risk scoring, 12-month financing history, AI-detected risk signals, and contextual analysis of this departure within TELO's broader capital structure and pipeline momentum.
Want the full 5-section $49 Report on TELO?
Dilution risk score · 12 months of 8-K context · financing history · AI risk signals · bottom-line framing. Delivered in ~5 minutes.
See a real sample report →
This preview was AI-generated from FilingFirehose's SEC EDGAR ingestion pipeline.
Not investment advice. Verify all claims against original filings.